Syndya Therapeutics
8952 Schlieren
Switzerland
NASH is a highly multifactorial disease involving weight management, lipid uptake in the liver, energy consumption, inflammation, cellular activation and finally liver fibrosis. Most compounds in the clinic only affect one of these factors primarily, which leads to a lack of potency. Based on a unique, human 3D in-vitro model for NASH (licensed from InSphero AG), Syndya circumvents this issue by combining an inefficient, clinical backbone drug with synergistic compounds to increase potency – and reduce undesired side effects. Because our 3D phenotypic NASH screen is based on human cells, not on animal models with poor predictivity, better translation in the clinic is our key advantage.